CRP and depressive disorder: It has been advocated that future clinical trials in depression should follow precision medicine principles by selecting a priori a subset of patients with elevated inflammatory markers, such as CRP, who most likely would respond to anti-inflammatory drugs (Chamberlain et al., 2019).